Actelion plans biotech start-up

pharmafile | June 20, 2011 | News story | Research and Development Actelion, biotech 

Swiss biopharmaceutical company Actelion is planning to launch a biotech start-up that would run separately from the main company.

It will be led by current chief medical officer Isaac Kobrin, who has been tasked with planning and then ultimately heading up the new venture.

Kobrin’s new role was announced as part of a wider management reshuffle, which includes a focus for chief executive Jean-Paul Clozel on more “strategic maters” and the appointment of Otto Schwarz as chief operating officer.

Otto joined Actelion in 2008 as head of business strategy and operations and takes on responsibility for the company’s commercial operations and business strategy, corporate services, global quality management and corporate communications.

Advertisement

Meanwhile, Simon Buckingham, previously head global gorporate and business development, will take up a new role (on a part-time basis) leading special projects and advising on corporate strategic matters.

Actelion will also extend its executive committee, adding Christian Albrich (head global human resources), Marian Borovsky (group general counsel), Martine Clozel (chief scientific officer) and Roland Haefeli (head investor relations and public affairs).

Dominic Tyer

Related Content

Cellbyte raises $2.75m to fund pharma drug launch platform

Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content